Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Other, Topics Dec 20 | 2024Dexcom Participates in Oura Funding; Galectin Misses MASH Endpoint in Ph2b/3 TrialPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Dec 20 | 2024Cagrisema Misses Weight Loss TargetPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i, Topics Dec 20 | 2024FDA Releases Status on GLP-1RA Supply; AZ Initiates Baxdrostat/Dapa Trial in CKD and CV; TIXiMED Announces $2.65M InvestmentPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Dec 18 | 2024Merck Buys Oral GLP-1RA; MetaVia Topline Ph2a MASH Data; Structure Reveals New DACRA Obesity Asset; Novo/Photys Enter Research Partnership; G&L Initiates H2H Tirzepatide Trial; EMA to Discuss Semaglutide Rare Eye Disease Association; Novo/Catalent Deal CompletePurchase Blast
$599
Posted in: Glucose Monitoring, Other, Topics Dec 17 | 2024Dexcom Integrates AI Into Stelo; Biomea Topline Icovamenib T2DM DataPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, Other, Topics Dec 16 | 2024Novo/Catalent Deal Approval; Novo Invests in New Manufacturing Facility; Afrezza Pediatric Results; New Ph2 Quad-Agonist + Tirzepatide TrialPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Other, Topics Dec 13 | 2024CHMP Denies Mounjaro OSA Indication; FLOW Positive CHMP Opinion; New Oramed Oral Insulin Study; Diamyd and FDA Align on Accelerated Approval; Noom to Offer Metformin for Weight LossPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Dec 11 | 2024ADA/EASD 2025 Guidelines; Ro/Lilly Zepbound SDV Partnership; Tirzepatide for Addiction TreatmentPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Dec 10 | 2024GLP1-RAs Reduce Blood Clot Risk in T2DM; Zealand Initiates Ph2b Petrelintide Obesity Trial Enrollment; NewAmsterdam Positive CETPi Ph3 HeFH DataPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Other, SGLT2i, Topics Dec 09 | 2024December CHMP Agenda; Senseonics Eversense 365 Launch Updates; BioAge Discontinues Ph2 Obesity TrialPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other, Topics Dec 06 | 2024EC Approves Novo/Catalent Deal; Novo Cuts Insulin Business; Twiist AID Webinar; New Pfizer and Novo Obesity Studies; Lilly CDMO AgreementPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Dec 05 | 2024UK Tirzepatide Rollout Plan; Lilly and Amgen Expand Manufacturing Facilities; New Novo GLP-1/GIP RA CKD and Obesity Trials; Insulet Defends US Patent from EOFlowPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Dec 04 | 2024Zepbound Beats Wegovy in H2H Study; Novavax to Sell Manufacturing Facility to Novo; Antag $84M Series A Financing for Ph1 Obesity TrialPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Other, Topics Dec 03 | 2024Metsera Initiates Ph2b MET-097 Obesity Trial; Arrowhead Files for Ph1/2a Obesity Trial Initiation; Sanofi Invests in New Beijing Insulin PlantPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics Nov 27 | 2024Arrowhead CY Q3 ’24 (FY Q4 ’24) Earnings; Embecta Discontinues Patch Pump; New Medicare and Medicaid Obesity Proposal; EOFlow Wins Legal Battle in the EUPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i, Topics Nov 26 | 2024Amgen MariTide Ph2 Topline Results; Alnylam sNDA Accepted for Vutrisiran with PRV; Novartis Investor EventPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i, Topics Nov 22 | 2024Lexicon Strategic Update; Boston MASH Investor Event; Ypsomed to Manufacture Cargisema Pens; Pep2Tango Obesity Startup; Generic Byetta FDA ApprovalPurchase Blast
$599
Posted in: ESPR, Glucose Monitoring, Insulin Delivery, Other, Topics Nov 20 | 2024Lilly and Laekna Obesity Partnership; Viking Ph2b MASH Data; Medtronic InPen App FDA Clearance; Omnipod 5 and FreeStyle Libre 2 Plus Integration; Flagship and Ampersand Obesity Partnership; NewAmsterdam Ph3 TANDEM CV DataPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Nov 19 | 2024Dexcom and Oura Partnership; Novo ESSENCE Data at AASLD; Medtronic CY Q3 ’24 (FY Q2 ’25) Earnings; Silence, Esperion, NewAmsterdam, and Arrowhead Data at AHA 2024; Aligos Ph2 MASH Data; Biomea COVALENT-111 AnalysisPurchase Blast